Anzeige
Mehr »
Lynx Broker
Login
Dienstag, 22.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14Z7X ISIN: CA00444G1081 Ticker-Symbol: 3TP 
Frankfurt
21.10.19
08:00 Uhr
0,044 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ACERUS PHARMACEUTICALS CORPORATION Chart 1 Jahr
5-Tage-Chart
ACERUS PHARMACEUTICALS CORPORATION 5-Tage-Chart

Aktuelle News zur ACERUS PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoAcerus Pharmaceuticals Corp: Acerus talks up Natesto spermatogenesis study results-
30.09.Acerus Pharmaceuticals Corp: Acerus amends credit facility with SWK Funding-
08.08.Acerus Pharmaceuticals Corporation (ASPCF) CEO Edward Gudaitis on Q2 2019 Results - Earnings Call Transcript-
ACERUS PHARMACEUTICALS Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!
07.08.Acerus Pharmaceuticals Corp: Acerus Pharmaceuticals loses $3.2M (U.S.) in Q2-
02.08.Acerus Pharmaceuticals Corp: Acerus to replace some "non-conforming" Natesto lots-
30.07.Acerus Pharmaceuticals Corp: Acerus, Aytu BioScience to co-promote Natesto-
30.07.Aytu BioScience, Inc.: Aytu BioScience Expands Natesto(R) Partnership with Acerus Pharmaceuticals to Accelerate Natesto Growth in the U.S.68Acerus to Launch U.S. Specialty Sales Force; Nearly Doubles Natesto Sales Force ENGLEWOOD, CO / ACCESSWIRE / July 30, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company...
► Artikel lesen
29.07.Acerus Pharmaceuticals Corp: Acerus Pharmaceuticals to provide Q2 results on Aug. 7-
24.07.Acerus Pharmaceuticals Corp: Acerus's Natesto nasal gel covered in U.S.-
19.07.Acerus closes $5M loan-
19.07.Acerus Pharmaceuticals Corp: Acerus arranges $5M (U.S.) loan with First Generation-
10.07.Acerus Pharmaceuticals Corp: Acerus S. Korea licensee begins commercializing Natesto-
08.07.Acerus Pharmaceuticals Corp: Acerus publishes Natesto results in endocrine journal-
28.06.Acerus Pharmaceuticals Corp: Acerus Pharmaceuticals amends credit facility-
28.06.Acerus Announces Voting Results for the 2019 Annual Meeting-
27.06.Acerus Pharmaceuticals Corp: Acerus shareholders elect six directors at AGM-
27.06.Acerus Pharmaceuticals Corp: Acerus's avanafil NDS in active review by Health Canada-
06.06.Acerus Pharmaceuticals Corp: Acerus cancels UriVarx licence deal-
30.05.Acerus Pharmaceuticals Corp: Acerus licenses nasal testosterone technology1
13.05.Acerus Pharmaceuticals' (ASPCF) CEO Ed Gudaitis on Q1 2019 Results - Earnings Call Transcript1
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1